Medipost Affiliate OmniaBio Breaks Ground on cGMP Production Facility for Cell and Gene Therapy

Omniabio bird's-eye view.
[Photo by Medipost]

[Asia Economy Reporter Lee Gwan-joo] Medipost announced on the 7th that its affiliate, Canadian Omnia Bio, a specialized company in contract development and manufacturing organization (CDMO) for cell and gene therapy, held a groundbreaking ceremony for a new cGMP production facility.

Omnia Bio's new cGMP production facility will be built at McMaster Innovation Park in Hamilton, Ontario, Canada. By the end of 2025, a total of 7,500㎡ of cell and gene therapy research and cGMP production facilities will be expanded.

Accordingly, Omnia Bio will have a total production facility area of 11,200㎡, including the existing 3,700㎡ cGMP facility located in Toronto. It is expected to become the foundation for growth as Canada’s largest cell and gene therapy CDMO specialized company, providing integrated services from process development to early and late-stage clinical development and commercialization.

Omnia Bio has already secured various local customers in North America and is conducting process development and contract manufacturing for autologous and allogeneic cell therapies, induced pluripotent stem cells (iPSC), genetically modified cell therapies, stem cell therapies, and CAR-T.

A groundbreaking ceremony for OmniaBio's new cGMP production facility was held at McMaster Innovation Park in Hamilton, Ontario, Canada.
[Photo by Medipost]

Mitchell Sibilotti, CEO of Omnia Bio, said at the groundbreaking ceremony, “We will play a key role in creating a new medical paradigm by developing cell and gene therapies that can change human lives with outstanding talents in the best production facilities.” He added, “Through a strategic partnership with Medipost, a global leader in stem cell therapies, we plan to expand the cell and gene therapy CDMO business not only in the North American region but also in the Asia-Pacific region.”

A Medipost official stated, “Omnia Bio is a company with excellent cell and gene therapy process development and production capabilities, and combined with our world’s first full-cycle stem cell therapy development know-how, we are confident it will create synergy in the global cell and gene therapy CDMO business.”

In May of this year, Medipost decided to invest a total of 90 million Canadian dollars (approximately 90 billion KRW) in Omnia Bio through the acquisition of existing shares and convertible bonds to newly enter the North American CDMO market. Currently, Medipost holds a 39.6% stake in Omnia Bio. After the convertible bonds are converted into common shares in 2027, Medipost will become the largest shareholder of Omnia Bio.

This content was produced with the assistance of AI translation services.